Exclusive: Women’s health biotech Freya Biosciences raises $38M for microbial immunotherapies
Freya Biosciences, a Danish and US biotech named after the Norse goddess of fertility, has raised a $38 million Series A, the clinical-stage startup told Endpoints News exclusively.
The Copenhagen and Boston startup, formed during the early days of the Covid-19 pandemic, will use the funding to test its investigational donor- and strain-derived microbial immunotherapies.
“If we can shift the microbial ecology, we have that corresponding shift in the immune profile, which would then have an effect on these quite severe indications that are downstream of this inflammation that arises in the reproductive tract,” CEO Colleen Acosta said in an interview with Endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.